Speaker

Zhang Dong, Director Physician and Professor of Cardiology at Xiyuan Hospital, China Academy of Chinese Medical Sciences, holds a Doctor of Medicine degree. He is the fourth cohort inheritor of the National Master of Traditional Chinese Medicine Apprenticeship Program and a second cohort Inheritance Postdoctoral Fellow under the National Administration of Traditional Chinese Medicine. Mentored by Professor Weng Weiliang (National Master of Traditional Chinese Medicine) and Academician Wang Yongyan. Graduated from Beijing University of Chinese Medicine. Engaged in clinical practice, scientific research, and teaching for over 30 years at the Department of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences. Renowned Young and Middle-aged Traditional Chinese Medicine Expert of the China Academy of Chinese Medical Sciences.

Zhang Fen Ping began his career as a Physician at Renji Hospital in Shanghai before transitioning to the corporate sector, where he rose to become Senior Vice President of Siemens Greater China. He later joined United Imaging Healthcare as a founding executive partner and Senior Vice President, overseeing the Marketing, Sales, Customer Service, Training, and Operations Center departments, and playing a key role until the company’s public listing in August 2022. In 2023, he partnered with French investment firm EXIMIUM to introduce leading European hidden champion enterprises to China, including facilitating the entry of the French listed biotechnology company genOway and establishing Shanghai GenOway Biotechnology Co., Ltd., where he serves as Executive Director and General Manager. He is also the China Region Partner at Confluence Global Capital, France.

Dr. Genwei Zhang obtained a Ph.D. in biochemistry and a master’s degree in computer science in the United States, and he completed postdoctoral research in Prof. Bradley Pentelute’s laboratory in the Department of Chemistry at the Massachusetts Institute of Technology (MIT). Prof. Pentelute is a global leader in the field of automated synthesis of peptides and proteins. Dr. Zhang has achieved internationally recognized research results in the fields of automated peptide synthesis, design and screening of peptide-targeted drugs, and the application of artificial intelligence in the research and development (R&D) of biomedicine. He has also accumulated rich industrial experience and has published over 30 SCI scientific papers. With a multidisciplinary background in biochemistry and computer science, he currently serves as the Senior Director of peptide R&D platform at XtalPi Innovation Center.

Dr. Haisheng Zhang is the Founder and CEO of Signet Therapeutics, and currently serves as Director of the Cancer Targeted Therapy Center at Tsinghua Shenzhen Institute and a dual-appointed professor at Nanfang Hospital, Southern Medical University. He completed postdoctoral research at Harvard Medical School’s Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
Dr. Zhang has long focused on targeted therapy and companion diagnostics for gastric
cancer, publishing over ten papers in top journals such as Cancer Discovery and Gut,
and was the first to identify a key target for diffuse gastric cancer.
In 2020, he founded Signet Therapeutics, the first company to integrate organoids and AI for innovative cancer drug discovery. The company’s lead drug, SIGX1094, is the world’s first targeted therapy for diffuse gastric cancer and is currently in Phase I trials at Peking University Cancer Hospital. It has received FDA Orphan Drug and Fast Track designations.
Dr. Zhang has been honored as a “Top Emerging Entrepreneur” in Shenzhen’s Ten Outstanding Young Entrepreneurs and listed in 36Kr’s “36 Under 36 Entrepreneurs.”

Dr. Hua Zhang is an experienced immuno-oncologist whose fingerprints are on some of the most exciting advances in cell and gene therapy. He brings over four decades of experience spanning academia, global research, and biopharmaceutical innovation. After serving nearly 20 years as a senior scientist at the National Cancer Institute, where he helped pioneer CAR-T therapies for leukemia and solid tumors, he transitioned to industry leadership. Since 2018, he has served as Vice President and Chief Scientific Officer at SPH Biotherapeutics, spearheading groundbreaking work in oncolytic virus vaccines, logic-gated CAR-T cells, and multi-antibody platforms—garnering over 20 international patents and multi-million dollars in grant funding.

Dr. Jiayi Zhang received her BSc. degree from Hong Kong Baptist University and Ph.D. degree from Brown University. She was a Brown-Coxe postdoctoral fellow at Yale University and joined the Institute of Brain Science at Fudan University in 2012. Her recent work focused on the decoding and restoration of vision. Her work was published in journals including Science, Nature Biomedical Engineering, Neuron and Nature Communications. She received the Xplorer Prize in 2025, State Science and Technology Advancement Award in 2023 and the Young Innovative Woman Award in Shanghai in 2020. She serves as the Vice chairman of the Neurotechnology Panel, Chinese Neuroscience Society (CNS). She is on the editorial board of Progress in Retina and Eye Research. She is currently the vice director of State Key Laboratory for Brain Function and Diseases. She also serves as the vice dean of the Institute of Brain Science, as well as the Institute for Medical and Engineering Innovation at Fudan Affiliated Eye & ENT Hospital.

Zhang Jie, Founder & Chairman of Jiu Zhang Biotech (Chengdu) and CEO, is the original developer of the globally pioneering new drugs “Chlorogenic Acid Active Pharmaceutical Ingredient (API)” and “Chlorogenic Acid for Injection.” He holds 53 Chinese invention patents and 29 international invention patents related to chlorogenic acid. In 2016, Chairman Zhang Jie was interviewed by Nature magazine, with the feature published in the December 22, 2016, issue. His key research findings have been documented in 5 international SCI-indexed papers.
He led the development of the National Eighth Five-Year Plan Key Scientific and Technological Project “FZ-1 Energy-Saving Friction Reducer and Efficiency Enhancer,” which received the 1992 ​Second Prize of Sichuan Provincial Science and Technology Progress Award​ and was included in the ​National Key New Product Program. He also organized the 2016 ​National Thirteenth Five-Year Plan Major New Drug Discovery and Development Program​ for the “Phase I/II Clinical Study of First-in-Class Category 1 New Drug Chlorogenic Acid for Injection,” which passed national review in 2020.

Member, Science and Technology Working Committee, World Federation of Acupuncture-Moxibustion Societies (WFAS)
Member, Constitution Branch, China Association of Chinese Medicine
Standing Committee Member & Deputy Secretary-General, Qihuang Needle Therapy Committee, China Acupuncture-Moxibustion Association
Standing Committee Member, Andrology Branch, Guangdong Association of Chinese Medicine
Vice-Chairman, Allergy Branch, Guangdong Health Science Popularization Promotion Association
Council Member, Guangdong Rehabilitation Medicine Association
Guangzhou Health Science Popularization Expert
Peer Reviewer, Journal of Sun Yat-sen University (Medical Sciences)
Peer Reviewer, The New Medicine
First Deputy Editor-in-Chief, Qihuang Needle Therapy, People’s Medical Publishing House
First Deputy Editor-in-Chief, Selected Clinical Case Studies on Qihuang Needle Therapy, China Science & Technology Press
Author of more than ten peer-reviewed publications

Professor Zhang Mianzhi, Doctor of Nephrology, Postdoctoral Fellow in Traditional Chinese Medicine, Chief Physician, Second-Class Professor, is a doctoral supervisor and postdoctoral co-supervisor at three universities including Beijing University of Chinese Medicine and Tianjin Medical University. He is an expert enjoying special government allowances from the State Council, one of the first “Famous Doctors in Tianjin”, a “Famous Traditional Chinese Medicine Doctor in Tianjin”, and a leading talent of Beijing’s “Yiqilin” program.

He serves as a member of the National Committee of the Chinese People’s Political Consultative Conference (CPPCC) and a member of the Education, Science, Health and Sports Committee of the CPPCC National Committee. He is also Vice President of the China Association for the Promotion of Chinese Medicine Research, Director of the Branch of Tonifying Kidney and Activating Blood Circulation of the China Association of Chinese Medicine, and Deputy Director of the Nephrology Branch of the China Association of Chinese Medicine.

Currently, he holds the positions of President of Tianjin Integrated Traditional Chinese and Western Medicine Hospital, Director of the Institute of Traditional Chinese Medicine Nephrology of Tianjin Academy of Traditional Chinese Medicine, Academic Leader of the National Regional TCM (Specialty) Diagnosis and Treatment Center, Academic Leader of Key Specialties of the National Health Commission and the State Administration of Traditional Chinese Medicine, Director of Tianjin Integrated Traditional Chinese and Western Medicine Nephrology Consultation Center, Visiting Professor at the School of Chinese Medicine of The Chinese University of Hong Kong, Distinguished Professor at the First Affiliated Hospital of Zhengzhou University, Leader of the Introduced High-Level TCM Medical Team in Shenzhen, and Leader of Zhang Mianzhi’s Beijing Municipal Famous TCM Doctor Team.

Professor Ning Zhang is a distinguished scientist and National Distinguished Young Scholar (recipient of the National Science Fund for Distinguished Young Scholars). He has been honored with several prestigious national awards, including selection into the National “Ten Thousand Talents Plan”, the Mid-aged and Young Leading Scientists, Engineers and Innovators Program (Ministry of Science and Technology), and the National Hundred, Thousand, and Ten Thousand Talents Project (Ministry of Human Resources). He is also a recipient of the Outstanding Contribution Expert Award and the Lee Foundation Award for Distinguished Achievement.

Currently, Professor Zhang holds multiple leadership roles: Director, Cancer Translational Research Center, Peking University First Hospital; Deputy Director, Peking University-Baiyao International Medical Center; Vice President, Peking University International Cancer Institute; Vice President, Peking University National Institute of Health Data Science; Executive Council Member & Secretary-General, Chinese Anti-Cancer Association; Chair, Translational Medicine Branch, Chinese Society of Gerontology and Geriatrics; Executive Associate Editor-in-Chief, Cancer Biology & Medicine; Executive Associate Editor-in-Chief, Medical Review; Chief Scientist, Baiyao Group.

Professor Zhang’s research focuses on biomedical sciences, with groundbreaking work published in top-tier journals such as Nature, Cancer Cell, Nature Biotechnology, Gastroenterology, and Nature Communications.